Friday, February 5, 2021 – Sunday, February 7, 2021

Virtual, Interactive Conference

All Times will be in Eastern Time

We are pleased to invite you to the upcoming 18th Annual Winter Lung Cancer Conference^®, a first-class continuing medical education event for the treatment of patients with lung cancer. Based on the popular format of expert overviews with dynamic Medical Crossfire^® exchanges from the Miami Lung Cancer Conference^®, this meeting will provide you with the most cutting-edge research and practical information for the care of your patients. You will also have a preview of new agents and techniques that will inform the future of lung cancer treatment.

This program, led by world-class thoracic oncologists, offers you the chance to learn from and interact with international experts in several therapeutic areas, including immunotherapy, targeted agents, and multidisciplinary approaches. Throughout the program, question-and-answer sessions will enable you to consult with faculty and your community-based peers. Come to learn, but also to share your personal experiences and best practices in lung cancer management.

By participating in this exciting program, you will have the opportunity to learn state-of-the-art care, including:

• Integration and optimization of molecular testing throughout the continuum of disease
• Leveraging the growing therapeutic armamentarium for oncogene-driven non–small cell lung cancer (NSCLC)
• Navigating options for first-line immunotherapy-based regimens in metastatic NSCLC
• Application of consolidation immunotherapy in locally advanced NSCLC
• Current approaches with surgery and radiation oncology in patients with thoracic malignancies

Be sure to join us for the 18th Annual Winter Lung Cancer Conference^® We look forward to seeing you there!

This activity is supported by educational grants from AstraZeneca; BeiGene; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eli Lilly and Company; Jazz Pharmaceuticals; Merck & Company Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; and Takeda Oncology.

Physicians' Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 11.75 Contact Hours.

Physicians’ Education Resource^®, LLC would also like to acknowledge the International Association for the Study of Lung Cancer as an endorser of the 18th Annual Winter Lung Cancer Conference^®.

• Learn the latest about new and emerging treatment options for patients with thoracic malignancies
• Hear expert perspectives on the clinical application of recent data, and on areas of clinical uncertainty and controversy
• Network with your peers and world-renowned thought leaders
• Improve the patient-centered care you provide to your patients

This educational activity is directed toward oncologists involved in the treatment of patients with lung cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment of lung cancers may also participate.

At the conclusion of this activity, you should be better prepared to:

• Integrate molecular testing strategies to inform treatment selection in patients with oncogene-driven NSCLC
• Evaluate emerging approaches for patient selection for immunotherapy and targeted agents
• Assess treatment strategies for early-stage and locally advanced lung cancer
• Describe the use of cytotoxic, targeted, and other systemic agents in the management of patients with lung cancer with or without oncogenic drivers
• Incorporate immunotherapeutic strategies in patients with thoracic malignancies along the disease continuum
• Discuss approaches to mitigate and manage treatment-related adverse events in patients with lung cancer

Rogerio C. Lilenbaum, MD
Senior Physician Executive
Banner MD Anderson Cancer Center
Phoenix, AZ

Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Member, Thoracic Oncology Program
Orlando, FL

Julie R. Brahmer, MD, MSc, FASCO
Director, Thoracic Oncology Program
Kimmel Cancer Center at Johns Hopkins Bayview
Professor of Oncology
Johns Hopkins Kimmel Cancer Center
Baltimore, MD